A study showed the addition of Merck & Co.'s anticlotting drug vorapaxar to standard care reduced the risk of heart attacks and related events by 13% in heart-disease patients—but increased the risk of significant bleeding by 66%.
You are receiving this email because you subscribed to this feed at blogtrottr.com.